Author
Listed:
- Hamid Bolouri
(Benaroya Research Institute)
- Rhonda E. Ries
(Fred Hutchinson Cancer Research Center)
- Alice E. Wiedeman
(Benaroya Research Institute)
- Tiffany Hylkema
(Fred Hutchinson Cancer Research Center)
- Sheila Scheiding
(Benaroya Research Institute)
- Vivian H. Gersuk
(Benaroya Research Institute)
- Kimberly O’Brien
(Benaroya Research Institute)
- Quynh-Anh Nguyen
(Benaroya Research Institute)
- Jenny L. Smith
(Fred Hutchinson Cancer Research Center
Seattle Children’s Research Institute)
- S. Alice Long
(Benaroya Research Institute)
- Soheil Meshinchi
(Fred Hutchinson Cancer Research Center)
Abstract
High levels of the inflammatory cytokine IL-6 in the bone marrow are associated with poor outcomes in pediatric acute myeloid leukemia (pAML), but its etiology remains unknown. Using RNA-seq data from pre-treatment bone marrows of 1489 children with pAML, we show that > 20% of patients have concurrent IL-6, IL-1, IFNα/β, and TNFα signaling activity and poorer outcomes. Targeted sequencing of pre-treatment bone marrow samples from affected patients (n = 181) revealed 5 highly recurrent patterns of somatic mutation. Using differential expression analyses of the most common genomic subtypes (~60% of total), we identify high expression of multiple potential drivers of inflammation-related treatment resistance. Regardless of genomic subtype, we show that JAK1/2 inhibition reduces receptor-mediated inflammatory signaling by leukemic cells in-vitro. The large number of high-risk pAML genomic subtypes presents an obstacle to the development of mutation-specific therapies. Our findings suggest that therapies targeting inflammatory signaling may be effective across multiple genomic subtypes of pAML.
Suggested Citation
Hamid Bolouri & Rhonda E. Ries & Alice E. Wiedeman & Tiffany Hylkema & Sheila Scheiding & Vivian H. Gersuk & Kimberly O’Brien & Quynh-Anh Nguyen & Jenny L. Smith & S. Alice Long & Soheil Meshinchi, 2022.
"Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes,"
Nature Communications, Nature, vol. 13(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34965-4
DOI: 10.1038/s41467-022-34965-4
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34965-4. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.